|
1）Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5: 37-50
|
|
|
|
2）Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol. 2005; 32: 443-51
|
|
|
|
|
|
3）Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8: 718-28
|
|
|
|
|
|
4）Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005; 105: 959-67
|
|
|
|
|
|
5）Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003; 9(10 Pt 1): 3578-88
|
|
|
|
|
|
6）Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005; 23: 3912-22
|
|
|
|
|
|
7）Wischnewski F, Pantel K. Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res. 2006; 4: 339-49
|
|
|
|
|
|
8）Coral S, Sigalotti L, Altomonte M, et al. 5-aza-2'- deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 2002; 8: 2690-5
|
|
|
|
|
|
9）Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004; 64: 4980-6
|
|
|
|
|
|
10）Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000; 165: 7017-24
|
|
|
|
|
|
11）Kitamura H, Torigoe T, Asanuma H, et al. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007; 178: 692-6
|
|
|
|
|
|
12）Maeda T, Towatari M, Kosugi H, et al. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood. 2000; 96: 3847-56
|
|
|
|
|
|
13）Serrano A, Tanzarella S, Lionello I, et al. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int J Cancer. 2001; 94: 243-51
|
|
|
|
|
|
14）Zika E, Greer SF, Zhu X-S, et al. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol. 2003; 23: 3091-102
|
|
|
|
|
|
15）Gialitakis M, Kretsovali A, Spilianakis C, et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Res. 2006; 34: 765-72
|
|
|
|
|
|
16）Kanaseki T, Ikeda H, Takamura Y, et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol. 2003; 170: 4980-5
|
|
|
|
|
|
17）Skov S, Pedersen MT, Andresen L, et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005; 65: 11136-45
|
|
|
|
|
|
18）Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005; 65: 6321-9
|
|
|
|
|
|
19）Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005; 11: 71-6
|
|
|
|
|
|
20）Eramo A, Pallini R, Lotti F, et al. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res. 2005; 65: 11469-77
|
|
|
|
|
|
21）Horak P, Pils D, Haller G, et al. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res. 2005; 3: 335-43
|
|
|
|
|
|
22）Fulda S, Debatin K-M. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006; 25: 5125-33
|
|
|
|
|